µþ²¹¶Ù³Ò·¡Â®
On-target naked gene-based therapies in an instant.
At a glance
-
Development stage
Active / generating revenue
-
Investment stage
Seed
-
91É«ÇéƬ affiliation
Staff research or technology
-
Technology readiness level
TRL-7
µþ²¹¶Ù³Ò·¡Â® answers the call for instant vector-free precision gene delivery.
Proprietary ‘electro-lens’ technology enables dial-up control of naked DNA and RNA therapeutics by electrotransfer to target tissues. This enables conventional drug-based clinical development pipelines, with in-house lead nucleic acid molecules for nerve repair, brain neuromodulation and vision, and intratumoral neovascular targets.
-
µþ²¹¶Ù³Ò·¡Â® achieves precise spatiotemporal control of the dose of naked nucleic acid molecules (stable and bio-inert outside of targeted cells), enabling precision gene-based medicine with repeated dosing and treatment options. The safety and efficacy of the process was validated in a first-in-human clinical trial for nerve repair.
-
- Vector-based delivery of DNA/RNA therapeutics by virus and lipid nanoparticles is challenged by packaging limits, stability, and ‘leaky’ biodistribution (lack of precision gene expression targeting within tissues).
- Immune priming precludes further treatments.
-
- Pharma seeking precision gene delivery solutions
- Pharma seeking solutions to neovascular diseases (VEGF-inhibition), nerve injury (BNDF & NT3 neurotrophins), and brain excitability (K+ channels)
-
- R&D (> AUD10 million); Australia Economic Accelerator Ignite funding for commercialisation of ‘Vision-BaDGE’ wetAMD therapy
- Biotech partnerships for BaDGE device and GMP DNA manufacture
- Validated in first-in-human clinical trial
Discover more 91É«ÇéƬ spinouts
Search our catalogue of active spinouts and tech for license.